Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Department of Medicine, University of Kentucky, Lexington, KY, USA.
Cancer Chemother Pharmacol. 2018 May;81(5):965-968. doi: 10.1007/s00280-018-3571-2. Epub 2018 Apr 2.
EML4-ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4-ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4-ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4-ALK genomic testing may be clinically useful in patients with heavy smoking history.
EML4-ALK 改变在腺癌中更为常见，在鳞状细胞组织学中很少发现。在有记录的病例中，大多数 EML4-ALK 易位发生在鳞状细胞组织学中，发生在没有或轻度吸烟史的患者中。我们报告了一例 50 岁的鳞状细胞癌患者和 18 包年吸烟史的 EML4-ALK4 易位。该患者对阿来替尼治疗在中枢神经系统中几乎完全缓解。我们的观察表明，EML4-ALK 基因组检测在有大量吸烟史的患者中可能具有临床意义。
